Introduction
============

Hematopoietic cell transplantation (HCT) can be accomplished with grafts from alternative donors for patients lacking an HLA-matched related or unrelated donor. The optimal choice of an alternative donor stem cell source remains an open question and is influenced by several factors including chronic graft-*versus*-host disease (GvHD). Chronic GvHD is a heterogeneous syndrome associated with major morbidity and adverse effects on quality of life and functionality among long-term allogeneic HCT survivors.^[@b1-1040835]--[@b3-1040835]^ Because a diagnosis of chronic GvHD does not always indicate significant morbidity and poor quality of life, the frequency of severe chronic GvHD manifestations (e.g. severe keratoconjunctivitis sicca, bronchiolitis obliterans, cutaneous scleroderma, joint/fasciae features, and esophageal stricture requiring dilation), the duration of immunosuppressive therapy and resumption of pretransplant activities (e.g., work/school) may serve as better measures of outcome after HCT.

The aim of this study was to analyze chronic GvHD manifestations most likely to be associated with disability, requirement of secondary systemic treatment, discontinuation of systemic immunosuppressive therapy and functional outcomes among recipients of grafts from alternative HCT donors. Differences in these clinical outcomes could help inform patients about outcomes after HCT from alternative donors.

Methods
=======

Patients and donors
-------------------

This retrospective study included all consecutive adult patients who received a first alternative donor HCT for any underlying diagnosis at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance between 2006 and 2015 and subsequently developed chronic GvHD that required systemic treatment. The alternative grafts included unrelated 4--6/6-HLA-matched single or double umbilical cord blood units (UCB), related HLA-haploidentical bone marrow or mobilized peripheral blood stem cells plus post-transplant cyclophosphamide (Haplo/PTCY), and mobilized peripheral blood stem cells from unrelated donors with a single HLA allele mismatched at an A, B, C or DRB1 locus by high resolution typing (1-mMUD), regardless of whether the mismatch resulted in antigen disparity at the locus. Patients had given written consent allowing the use of medical records for research in accordance with the Declaration of Helsinki, and the institutional review board approved the study.

Clinical assessments and definitions
------------------------------------

Involved sites and types of treatment at the onset of first systemic teraphy of chronic GvHD and treatment changes after initial teraphy were recorded prospectively via the Long-Term Follow-Up Program through medical records from our outpatient clinic and local clinics that provided primary care for patients. All patients were screened for evidence of chronic GvHD between days 80 and 100 after HCT, at 1 year after HCT, and whenever clinically indicated to establish the diagnosis of chronic GvHD or to determine treatment.

Acute GVHD was graded according to previously described criteria.^[@b4-1040835]^ Chronic GvHD was diagnosed using the 2014 National Institutes of Health consensus criteria.^[@b5-1040835]^ Disability related to chronic GvHD was defined as 2014 National Institutes of Health consensus grade 2 or 3 keratoconjunctivitis sicca, grade 2 or 3 scleroderma, any grade of bronchiolitis obliterans, grade 2 or 3 joint/fasciae involvement, or grade 3 esophageal stricture requiring dilation. While vulvovaginal chronic GvHD can result in fibrosis, this manifestation is under reported and unlikely to result in disability by itself, and thus not included in our study. National Institutes of Health score 2 or 3 gastrointestinal, oral or hepatic manifestations reflect GvHD activity but are less likely to cause irreversible damage and were also not included in our study. Return to work or school was considered only for patients who were working or in school before the HCT indication was diagnosed and had not resumed those activities before the onset of chronic GvHD. Treatment change was defined as any additional systemic treatment not used for the initial treatment of chronic GvHD. An increase in steroid dose in patients who were initially treated with steroid was not considered as a treatment change, because temporary increases in steroid doses or resumption of steroid treatment are often necessary during the initial treatment of chronic GvHD.^[@b6-1040835]^ Discontinuation of systemic immunosuppression was defined as cessation of treatment for at least 6 months after resolution of chronic GvHD.

Statistical analysis
--------------------

The main endpoints of this study were chronic GvHD manifestations associated with disability and impaired functional outcomes (i.e., return to work/school after the diagnosis of chronic GvHD, discontinuation of systemic immunosuppressive therapy, and change in Karnovsky Performance Status). We also compared the overall severity of chronic GvHD at initial diagnosis and the incidences of avascular necrosis, new systemic immunosuppression or treatment after first-line therapy for chronic GvHD, non-relapse mortality and overall survival after chronic GvHD diagnosis.

The chronic GvHD characteristics between donor groups were compared using a χ^2^ test for categorical variables and Wilcoxon rank-sum test for continuous variables. Overall survival was estimated by the Kaplan-Meier method. Cumulative incidences of chronic GvHD and of events after the onset of chronic GvHD were estimated by methods for competing risks, as previously described.^[@b7-1040835]^ Death was a competing event for all risks except non-relapse mortality; relapse was a competing event for non-relapse mortality. All comparisons of time-to-event endpoints were performed using Cox regression. The analysis of return to work or school was restricted to patients who were working or in school before HCT, and had not returned to work or school before the onset of chronic GvHD. The analysis of high morbidity was based on the first defining complication. All *P*-values are two-sided and unadjusted for multiple comparisons.

Results
=======

We identified 396 alternative donor HCT recipients who received a first allogeneic transplant for any disease between 2006 and 2015 at our center. The median age at HCT was 42 years (range, 18-73) for UCB, 48 years (range, 18-75) for Haplo/PTCY, and 55 years (range, 22-77) for 1-mMUD HCT recipients. Acute myeloid leukemia and myelodysplastic syndrome were the most common diagnoses at HCT, 64% and 65% among the UCB and 1-mMUD HCT recipients, respectively, while lymphomas were the most common diagnosis (52%) among the Haplo/PTCY HCT recipients. Other demographic characteristics are summarized in [Table 1](#t1-1040835){ref-type="table"}.

###### 

Characteristics of the study population according to alternative donor group.

![](104835.tab1)

Chronic graft-*versus*-host disease
-----------------------------------

Of the 396 alternative donor HCT recipients, 129 developed chronic GvHD that required systemic treatment and were included in this study. The cases of treatment-requiring chronic GvHD were diagnosed in 29 of the 163 UCB HCT recipients, 21 of 88 Haplo/PTCY HCT recipients and 79 of 145 1-mMUD HCT recipients, for 3-year cumulative incidences of 18%, 24% and 55%, respectively. The rate of chronic GvHD was significantly lower in UCB and Haplo/PTCY recipients than in 1-mMURD recipients \[hazard ratio (HR)=0.23; 95% confidence interval (95% CI): 0.2-0.4), *P*\<0.0001, and HR=0.29 (95% CI: 0.2-0.5), *P*\<0.0001, respectively\] ([Figure 1A](#f1-1040835){ref-type="fig"}). The incidence of chronic GvHD was comparable between patients who received 1-mMUD grafts with either allelic or antigenic mismatches (*data not shown*). Progression-free survival after HCT did not differ among the three donor groups ([Figure 1B](#f1-1040835){ref-type="fig"}). The median follow-up times after the onset of chronic GvHD were 48 (range, 4--121) months for UCB, 60 (range, \<1--123) for Haplo/PTCY, and 46 (range, 4--131) for 1-mMUD HCT. The median time from HCT to diagnosis of chronic GvHD was shorter in the UCB recipients than in 1-mMUD HCT recipients \[3.9 (range, 2.6-18.2) *versus* 7.8 (range, 2.7-38.2) months, *P*=0.001\]. As shown in [Table 2](#t2-1040835){ref-type="table"}, the incidence frequencies of overlap chronic GvHD (\>80%) and of prior acute GvHD (\>70%) were high in all three groups. These findings are consistent with the frequent diagnosis of upper gastrointestinal GvHD at our center.^[@b8-1040835]^ The severity of chronic GvHD at diagnosis was significantly lower in the UCB group than in the 1-mMUD group (*P*=0.008) ([Table 2](#t2-1040835){ref-type="table"}), but the severity of GvHD manifestations at the onset of chronic GvHD did not differ between the Haplo/PTCY and the 1-mMUD groups (*P*=0.74) ([Table 2](#t2-1040835){ref-type="table"}). According to the National Institutes of Health Global Severity scale, the incidence of moderate or severe chronic GvHD at diagnosis was 62% in the UCB group, 76% in the Haplo/PTCY group and 83% in the 1-mMUD group. [Table 2](#t2-1040835){ref-type="table"} displays additional characteristics of the chronic GvHD according to the alternative donor HCT groups.

![The cumulative incidence of chronic graft-*versus*-host disease is higher in the mismatched unrelated donor group than in the cord blood or HLA-haploidentical groups, but survival does not differ between the groups. Cumulative incidence of (A) chronic graft-*versus*-host disease and (B) progression-free survival after transplant according to alternative donor hematopoietic cell transplant group. NIH: National Institutes of Health; cGVHD: chronic graft-*versus*-host disease; URD Mism: mismatched unrelated donor; Cord: umbilical cord blood; Haplo: haplorelated bone marrow or peripheral blood; PFS: progression-free survival.](104835.fig1){#f1-1040835}

###### 

Characteristics of chronic graft-*versus*-host disease according to alternative donor group.

![](104835.tab2)

Sites of chronic GvHD and the presence of eosinophilia at any time during the course of chronic GvHD among the three alternative donor HCT groups are displayed in [Figure 2](#f2-1040835){ref-type="fig"}. Mouth and skin were the most common sites of chronic GvHD in the three groups (\>80%). Eyes were affected by chronic GvHD of any degree at any time in 75% of the 1-mMUD, 52% of the Haplo/PTCY, and 34% of the UCB HCT recipients. The same pattern was identified for hepatic involvement at any time (56% of 1-mmUD, 43% of Haplo/PTCY, and 24% of UCB HCT recipients). On the other hand, gastrointestinal tract involvement at any time developed in 72% of the UCB patients, but in 58% of the 1-mmUD and 52% of the Haplo/PTCY HCT recipients.

![Patterns of organ involvement differ according to the type of alternative donor. The figure shows the proportions of patients with involved sites or signs of chronic graft-*versus*-host disease at any time from initial diagnosis to last follow-up according to alternative donor HCT group. Patients could have more than one site involved. GI, gastrointestinal; HCT, hematopoietic cell transplant; UCB: umbilical cord blood.](104835.fig2){#f2-1040835}

Results of major outcomes according to the alternative donor HCT groups are shown in [Table 3](#t3-1040835){ref-type="table"}.

###### 

Outcomes analyzed according to alternative hematopoietic cell transplant donor group.

![](104835.tab3)

Chronic graft-*versus*-host disease manifestations of high morbidity
--------------------------------------------------------------------

The cumulative incidence of any manifestation of high morbidity at 3 years after the diagnosis of chronic GvHD is shown in [Figure 3A](#f3-1040835){ref-type="fig"} and was significantly lower in the UCB (17%) and Haplo/PTCY (23%) groups than in the 1-mMUD group (58%) \[HR 0.16 (95% CI: 0.1-0.4); *P*=0.0001, and HR 0.32 (95% CI: 0.1-0.7), *P*=0.009, respectively\], ([Figure 3A](#f3-1040835){ref-type="fig"}). [Table 3](#t3-1040835){ref-type="table"} shows the distribution of chronic GvHD manifestations of high morbidity according to the three HCT donor groups. The most frequent high morbidity was keratoconjunctivitis sicca followed by sclerosis and bronchiolitis obliterans (lungs). Moderate or severe joint/fasciae involvement and esophageal stricture requiring dilation were less frequent high morbidity manifestations. The cumulative incidence of keratoconjunctivitis sicca was significantly lower in the UCB group than in the 1-mMUD group (10% *versus* 39%, *P*=0.003) and was also lower in the Haplo/PTCY group (10%, *P*=0.05). The 3-year cumulative incidence of any high morbidity and the three most frequent high morbidity chronic GvHD manifestations according to the alternative donor groups are displayed in [Figure 3](#f3-1040835){ref-type="fig"}.

![Patients in the group grafted from a mismatched unrelated donor had a high cumulative incidence of disability caused by morbidity involving the skin, eyes and lungs. Cumulative incidence of: (A) any manifestations of chronic GVHD associated with disability; (B) moderate or severe keratoconjunctivitis sicca, (C) skin sclerosis and (D) bronchiolitis obliterans according to alternative donor HCT group. URD Mism: mismatched unrelated donor; Cord: umbilical cord blood; Haplo: haplorelated bone marrow or peripheral blood; GVHD: graft-*versus*-host disease.](104835.fig3){#f3-1040835}

Duration of immunosuppressive therapy and change in systemic therapy
--------------------------------------------------------------------

The proportion of patients in each group requiring changes in systemic therapy for control of chronic GvHD at 3 years after first-line treatment was 17% for the UCB group, 25% for the Haplo/PTCY groups and 39% for the 1-mMUD group, and was significantly lower for the UCB group than for the 1-mMUD group \[HR 0.30 (95% CI: 0.1-0.8), *P*=0.01\] ([Figure 4A](#f4-1040835){ref-type="fig"} and [Table 3](#t3-1040835){ref-type="table"}).

![Patients in the mismatched unrelated donor group had a high cumulative incidence of second-line treatment, and withdrawal of immunosuppressive treatment and return to work or school were delayed. Cumulative incidence of (A) change of systemic therapy after first-line therapy for chronic GVHD; (B) discontinuation of systemic immunosuppressive therapy, and (C) return to work/school after the diagnosis of chronic GVHD according to the alternative HCT group. Rx: treatment; IST: immunosuppressive therapy; URD Mism, mismatched unrelated peripheral blood stem cell; Haplo, related haploidentical; cGVHD, chronic graft-*versus*-host disease.](104835.fig4){#f4-1040835}

The cumulative incidence of discontinued systemic immunosuppression at 3 years was significantly lower in the 1-mMUD (15%) group than in the UCB (45%) and Haplo/PTC (50%) groups \[HR 3.96 (95% CI: 1.9--8.4), *P*=0.0003, and HR 4.93 (95% CI: 2.2--11.1), *P*=0.0001, respectively\] ([Figure 4B](#f4-1040835){ref-type="fig"}).

Functional endpoints
--------------------

A higher proportion of UCB patients than 1-mMUD HCT recipients (68% *versus* 35%) returned to work or school within 3 years after the onset of chronic GvHD \[HR 2.54 (95% CI: 1.1-5.7), *P*=0.02\], and a similar trend was observed in the Haplo/PTCY group \[62% *versus* 35%, HR 2.38 (95% CI: 1.0-5.9), *P*=0.06\] ([Figure 4C](#f4-1040835){ref-type="fig"}). Eighteen patients had returned to work or school before the onset of chronic GvHD (14 in the 1-mMUD and 4 in the Haplo/PTCY HCT groups). We also found trends suggesting improved annualized Karnovsky Performance Status change from the onset of chronic GvHD to 3.5 years afterwards in the UCB \[+5 (range, −12 to +44)\] and Haplo/PTCY \[+11 (range, −14 to +64)\] groups compared to the 1-mMUD group \[0 (range, −81 to +46)\] (*P*=0.05 and *P*=0.06, respectively). We found no difference in avascular necrosis at 3 years among the three alternative donor groups (12% in the 1-mMUD, 12% in the UCB, and 5% in the Haplo/PTCY HCT recipients).

Survival endpoints
------------------

The cumulative incidence of non-relapse mortality at 3 years among patients with chronic GvHD was 22% in 1-mMUD recipients, 11% in UCB recipients, and 6% in the Haplo/PTCY recipients, with no statistically significant differences between the three groups \[1-mMUD *versus* UCB, HR 0.32 (95% CI: 0.1-1.4), *P*=0.13; 1-mMUD *versus* Haplo/PTCY, HR 0.20 (95% CI: 0.0-1.5), *P*=0.12\] ([Table 3](#t3-1040835){ref-type="table"}). The cumulative incidence of overall survival at 3 years among patients with chronic GvHD was 72% in 1-mMUD recipients, 82% in UCB recipients, and 90% in Haplo/PTCY recipients, with no statistically significant differences between the three groups \[1-mMUD *versus* UCB, HR 0.59 (95% CI: 0.3-1.4), *P*=0.21; 1-mMUD *versus* Haplo/PTCY, HR 0.49 (95% CI: 0.2-1.4), *P*=0.18\] ([Table 3](#t3-1040835){ref-type="table"}). Progression-free survival after HCT did not differ between the three groups ([Figure 1B](#f1-1040835){ref-type="fig"}).

Discussion
==========

In parallel with the lower rates of overall chronic GvHD, we demonstrated that the cumulative incidence of chronic GvHD manifestations associated with disability was significantly lower after UCB and Haplo/PTCY HCT than that after 1-mMUD HCT.

The overall incidence of chronic GvHD in our study was lower in the UCB and Haplo/PTCY HCT cohorts than in the 1-mMUD HCT cohort, similar to results of previous studies.^[@b9-1040835]--[@b17-1040835]^ The overall incidence of chronic GvHD after 1-mMUD HCT was higher in our study than in previous reports.^[@b9-1040835],[@b11-1040835],[@b13-1040835],[@b17-1040835]--[@b21-1040835]^ This difference may be explained by the higher proportion of bone marrow grafts and more frequent use of T-cell depletion in the previous studies.^[@b9-1040835],[@b11-1040835],[@b13-1040835],[@b17-1040835],[@b18-1040835],[@b22-1040835]^ Older age could also be a contributor to the higher rates of chronic GvHD in the 1-mMUD group compared to the UCB and Haplo/PTCY groups.

Keratoconjunctivitis sicca was the most common chronic GvHD manifestation of high morbidity. Of note, the incidence of severe keratoconjunctivitis sicca at any time after the diagnosis of chronic GvHD was at least 4-fold higher in the 1-mMUD group than in the UCB group and at least 2-fold higher in the 1-mMUD group than in the Haplo/PTCY group. Prospective trials have shown that quality of life is impaired in patients with chronic GvHD involving the eyes.^[@b23-1040835],[@b24-1040835]^

Sclerotic manifestations of chronic GvHD were the second most common severe morbidity in the three donor groups, but were seen in less than 5% of the UCB and Haplo/PTCY groups as compared to nearly a quarter of the 1-mMUD HCT group. The reported overall cumulative incidence of sclerotic chronic GvHD after HCT is approximately 20%, with lower rates in recipients of HLA-mismatched HCT than in recipients of HLA-matched HCT.^[@b25-1040835],[@b26-1040835]^ The use of growth factor-mobilized blood cells is a known risk factor for the development of sclerotic GvHD after HCT. The frequent use of mobilized blood cells could explain the 25% incidence of sclerotic manifestations in our 1-mMUD HCT group. The remarkably low rate of sclerotic manifestations in the UCB cohort is consistent with prior reports of outcomes after UCB HCT.^[@b26-1040835],[@b27-1040835]^

In order to assess protracted chronic GvHD, we evaluated the duration of systemic therapy used to control the disease manifestations and the impact on functional outcomes among the three alternative donor groups. A large proportion of UCB (45%) and Haplo/PTCY (59%) HCT recipients were able to discontinue all systemic treatment for chronic GvHD by 3 years after onset of the condition, in contrast to only 15% of the 1-mMUD group. The use of mobilized blood as the stem cell graft and the involvement of multiple sites at initial diagnosis are risk factors for prolonged immunosuppressive treatment.^[@b28-1040835]--[@b30-1040835]^ The significantly lower incidence of second-line systemic immunosuppressive treatment of chronic GvHD in the UCB and Haplo/PTCY groups than in the 1-mMUD group also supports the conclusion that the severity of chronic GvHD is greater after HCT with 1-mMUD donors than with UCB or HLA-haploidentical related donors.

The presence of chronic GvHD has been consistently associated with failure to return to work or school, limited resilience and poor quality of life among HCT survivors.^[@b1-1040835]--[@b3-1040835],[@b31-1040835]^ In our study, a significantly higher proportion of the UCB group were more likely to return to work or school compared to the that of the 1-mMUD group, and a similar benefit trend was also evident for the Haplo/PTCY group, supporting the conclusion that GvHD manifestations associated with disability frequently impaired recovery of pre-transplant function in the 1-mMUD group.

Our study has several limitations. First, the three groups were heterogeneous with respect to the patients' age, gender, race, underlying disease and conditioning regimen intensity. Among these factors, only the patients' age has been associated with an increased incidence of chronic GvHD. An association of older patients' age with higher risk of chronic GvHD has not been consistently observed after UCB HCT, and very few data addressing this issue are available for Haplo/PTCY recipients.^[@b32-1040835]--[@b37-1040835]^ A second limitation of the study is that the small numbers of patients with chronic GvHD in the UCB and Haplo/PTCY groups precluded a direct comparison of outcomes between these two groups. Third, we included both one-antigen and allele-mismatched unrelated donor peripheral blood stem cell recipients irrespective of the "direction" of mismatching. However, there was no significant difference in incidence of chronic GvHD between these mismatched unrelated donor groups (*data not shown*), consistent with the results of a large, previous study from the Center for International Blood and Marrow Transplant Research.^[@b38-1040835]^ Fourth, the incidence of chronic GvHD in the 1-mMUD group in our study may not be representative of results with T-cell depleted 1-mMUD grafts.^[@b26-1040835],[@b34-1040835],[@b39-1040835],[@b40-1040835]^ Moreover, considering that mobilized blood stem cells were the graft source used for the 1-mMUD HCT group in our study, the risk and morbidity of chronic GvHD with unrelated donor bone marrow grafting might not differ from those for UCB or Haplo/PTCY HCT. Fifth, we were unable to assess quality of life in this study, because very few patients had outcomes based on validated measurement instruments. Sixth, the duration of immunosuppression may be driven ultimately by the selection of stem cell sources associated with a higher risk of severe chronic GvHD (i.e., unrelated mobilized blood cells) or with a lower risk of severe chronic GvHD (i.e., UCB or Haplo/PTCY). Seventh, some manifestations of chronic GvHD may have been underreported in this retrospective study (e.g., genital or lung involvement) Lastly, the analysis of functional endpoints at 3 years is limited by the small numbers.

In conclusion, our results show that compared to 1-mMUD recipients, UCB and Haplo/PTCY HCT recipients were less likely to develop chronic GvHD, were less likely to develop disability related to chronic GvHD, had a shorter duration of systemic treatment for chronic GvHD and returned to work or school earlier. While our data do not imply superiority of one alternative transplant strategy *versus* another (e.g. Haplo/PTCY *versus* 1-mMUD peripheral blood *versus* UCB), the current study provides detailed information regarding disability related to chronic GvHD when it occurs after alternative donor HCT. These findings should help transplant providers to counsel pre-HCT candidates better. Determination of disability associated with chronic GvHD is necessary in prospective studies testing alternative donor graft products such as Haplo/PTCY *versus* UCB to evaluate the overall efficacy of these strategies.
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